A 28-year-old schoolteacher in Pakistan spent four years trapped in a cycle that will feel painfully familiar to millions of people with high blood pressure. She took one antihypertensive medication after another, watched the doses climb, and still her systolic pressure hovered between 170 and 180 mmHg while her diastolic readings sat stubbornly at 110 to 120 mmHg. Her doctors escalated therapy through combinations of amlodipine, valsartan, and hydrochlorothiazide, yet the numbers refused to fall into a safe range. What finally explained her resistance to treatment was not her lifestyle, her kidneys, or her arteries, but a pea-sized hormone factory tucked into her right adrenal gland. A newly published case report in the open-access journal Clinical Case Reports describes how clinicians at a tertiary care hospital in Pakistan traced her stubborn hypertension to primary hyperaldosteronism, a disorder in which the adrenal glands secrete the sodium-retaining hormone aldosterone without the normal physiological brakes.
Primary hyperaldosteronism is far more than a medical curiosity. First identified by Dr. Jerome Conn in 1954, the syndrome was originally defined by a triad of low serum potassium, excessive urinary potassium loss, and metabolic alkalosis driven by excess aldosterone. In the decades since, researchers have come to understand that the condition arises from at least six distinct adrenal tissue types, with roughly ninety percent of cases attributable to either a unilateral aldosterone-producing adenoma or bilateral idiopathic adrenal hyperplasia. Less than ten percent stem from rarer entities such as adrenocortical carcinoma or familial hyperaldosteronism. Crucially, clinicians now recognize that the disorder can present subtly, without the dramatic potassium abnormalities that once defined it, and this recognition has elevated primary hyperaldosteronism to the status of the most common curable cause of secondary hypertension. Some estimates suggest that a meaningful fraction of all resistant hypertension cases conceal an aldosterone excess that standard screening would miss.
The physiology explains why the condition is so damaging and so treatable at the same time. Aldosterone acts on the distal nephron of the kidney, instructing it to reabsorb sodium while excreting potassium. When the hormone is produced autonomously, sodium and water accumulate in the circulation, expanding blood volume and driving blood pressure upward. Meanwhile, the relentless potassium wasting produces hypokalemia, which can manifest as muscle weakness, cramps, and paresthesias. In parallel, the expanded volume suppresses renin release from the kidneys, which is precisely the biochemical fingerprint that makes diagnosis possible. The patient in this report displayed the classic pattern: her serum potassium had fallen to 2.9 mmol/L, her plasma renin was suppressed at 5.3 uI U/mL, and her serum aldosterone measured 38.20 ng/dL, yielding an elevated aldosterone-to-renin ratio that pointed decisively toward autonomous aldosterone production.
Reaching that diagnosis required systematically ruling out the other usual suspects in secondary hypertension. The clinical team measured urinary vanillylmandelic acid at 18.27 mg per 24 hours, plasma metanephrine at 10.8 pg/mL, and plasma normetanephrine at 104.73 pg/mL, all of which fell within ranges that excluded pheochromocytoma, the catecholamine-secreting adrenal tumor that can produce similarly explosive hypertension. Renal function tests and imaging ruled out renovascular causes, and there was no evidence of Cushing syndrome. The differential diagnosis had included pheochromocytoma, renovascular hypertension, Cushing syndrome, and ordinary essential hypertension, but the combination of hypokalemia, suppressed renin, and elevated aldosterone left little ambiguity. The aldosterone-to-renin ratio remains the most accurate screening tool for the disorder, and its performance in this case illustrates why international guidelines recommend it for any patient whose hypertension resists multiple medications.
Localization came next, and here imaging played the decisive role. An abdominal ultrasound had shown no abnormalities, but magnetic resonance imaging revealed a well-defined nodule measuring 17 by 10 millimeters in the right adrenal gland, an oval and circumscribed lesion highly suggestive of an adenoma. The imaging picture aligned perfectly with the biochemistry, and the team concluded that a right-sided aldosterone-producing adenoma was driving the entire clinical syndrome. The case report is candid about one limitation: adrenal vein sampling, the gold-standard procedure for confirming that aldosterone excess is truly lateralized to one gland, was not available at the institution. AVS carries a reported sensitivity of 95 percent and specificity of 100 percent in distinguishing unilateral from bilateral disease, and guidelines emphasize its importance because misclassification can lead to the wrong treatment. In this instance, however, the concordance of clinical, biochemical, and radiological data was judged sufficient to proceed.
The distinction between unilateral and bilateral disease is not academic; it determines the entire therapeutic strategy. A unilateral aldosterone-producing adenoma is best treated with surgical adrenalectomy, which can be curative, whereas bilateral adrenal hyperplasia is managed medically with mineralocorticoid receptor antagonists such as spironolactone. Computed tomography, despite a reported specificity of 98 to 100 percent for characterizing adrenal adenomas, can misclassify the subtype in nearly 38 percent of patients, which is why adrenal vein sampling retains its fundamental role in surgical decision-making. After counseling and preoperative optimization of her blood pressure, the patient underwent an exploratory laparotomy with right adrenalectomy through a subcostal incision, performed by an experienced consultant surgeon with endocrinologists involved in perioperative care. The adrenal mass was successfully resected without complications or conversions.
The postoperative course delivered the kind of dramatic turnaround that makes this case report worth attention. Within three days of surgery, the patient’s blood pressure was well controlled on a reduced regimen of nebivolol and a valsartan-amlodipine-hydrochlorothiazide combination, and her serum potassium had normalized entirely without supplementation. She was discharged in stable condition, adhered faithfully to her follow-up schedule, and at three months postoperatively showed sustained clinical improvement with no relapse of symptoms. The timeline is striking when set against the preceding four years of escalating drug therapy: from referral to the surgical outpatient department in March 2023, through laboratory confirmation of the aldosterone-renin abnormality, MRI localization of the adrenal mass, and surgery in April, to normal blood pressure and potassium within days of the operation.
The authors of the report emphasize that the case carries a broader lesson about who should be screened and how early. Unilateral adrenalectomy typically results in blood pressure normalization within six months, although improvement can take up to a year in some patients, and persistent postoperative hypertension is more likely in those whose hypertension lasted more than six years or who required multiple medications before surgery. Every year of uncontrolled aldosterone excess also inflicts organ damage that operates independently of blood pressure itself, meaning that delayed diagnosis leaves a hidden cardiovascular toll even in patients who eventually achieve control. Early surgical treatment, by contrast, lowers blood pressure, restores electrolyte balance, and reduces the long-term risk of cardiovascular disease. Prognosis, the authors note, depends heavily on the duration of hypertension before intervention and the age of the patient, which makes young patients with resistant hypertension the highest-yield group for screening.
For a disorder first described more than seventy years ago, primary hyperaldosteronism still hides in plain sight, and this single case from Pakistan captures both the problem and the solution. A young woman with no smoking history, no alcohol use, no recreational drug exposure, and a normal physical examination spent four years on escalating antihypertensive therapy because no one measured her aldosterone and renin levels until hypokalemia forced the question. The report, prepared according to the SCARE 2025 guidelines for surgical case reporting, also underscores the value of multidisciplinary teamwork, from the internists who referred an amenable case to the surgeons and endocrinologists who completed the diagnostic and therapeutic arc. The message for clinicians is straightforward: when hypertension resists three medications, especially in a young patient with unexplained low potassium, the aldosterone-to-renin ratio deserves a place at the top of the workup, because behind a stubborn blood pressure reading there may be a curable adenoma waiting to be found.
Subject of Research: Primary hyperaldosteronism presenting as resistant hypertension in a young woman, diagnosed biochemically and cured by right adrenalectomy.
Article Title: Primary Hyperaldosteronism as a Cause of Resistant Hypertension: A Case Report
Article References: Chaudhry, W. M., Ibnerasa, S. N., Ahmad, W., & Amin, M. H. J. (2026). Primary Hyperaldosteronism as a Cause of Resistant Hypertension: A Case Report. Clinical Case Reports, 14(9), Article e73576. https://doi.org/10.1002/ccr3.73576
Image Credits: AI Generated
DOI: 10.1002/ccr3.73576
Keywords: primary hyperaldosteronism, resistant hypertension, aldosterone, adrenal adenoma, hypokalemia, aldosterone-to-renin ratio, adrenalectomy, adrenal vein sampling, secondary hypertension, Conn syndrome, case report, endocrine hypertension
Cite Scienmag News
APA
MLA
Chicago
Ophelia Keating. (September 22, 2026). Hidden Hormone Disorder Unmasked as Curable Cause of Resistant Hypertension in Young Woman. Scienmag. https://scienmag.com/hidden-hormone-disorder-unmasked-as-curable-cause-of-resistant-hypertension-in-young-woman/
Ophelia Keating. “Hidden Hormone Disorder Unmasked as Curable Cause of Resistant Hypertension in Young Woman.” Scienmag, 22 September 2026, https://scienmag.com/hidden-hormone-disorder-unmasked-as-curable-cause-of-resistant-hypertension-in-young-woman/. Accessed 22 September 2026.
Ophelia Keating. “Hidden Hormone Disorder Unmasked as Curable Cause of Resistant Hypertension in Young Woman.” Scienmag. September 22, 2026. https://scienmag.com/hidden-hormone-disorder-unmasked-as-curable-cause-of-resistant-hypertension-in-young-woman/
Copy citation
Download RIS
Tags: adrenal adenomaadrenal gland hormone disordersadrenal gland surgical interventionadrenal tumor diagnosisadrenal vein samplingadrenalectomyaldosteronealdosterone-to-renin ratiocase reportcase report on resistant hypertensionConn syndromeendocrine hypertensionhormone disorders and blood pressurehormone-driven hypertensionhyperaldosteronism in young womenhyperaldosteronism treatmenthypokalemiaprimary hyperaldosteronismprimary hyperaldosteronism diagnosisresistant high blood pressureresistant hypertensionsecondary hypertensionsecondary hypertension causes
